Absci Corp (ABSI) AI Stock Summary

Snapshot

Absci is a clinical-stage biotech with almost no product revenue ($2.8M in FY 2025, down 38% YoY) and a net loss of $115.2M, mostly from $81.4M in R&D spending, a bet on its drug pipeline rather than a sign of a broken business. It holds $201.1M in cash against just $3.7M in debt. Signal8 models roughly 18.7 months of runway. Shares outstanding rose 24% YoY, a meaningful dilution event.

What's Happening Right Now

• Thu 24th Sep '26 · Pipeline: Absci disclosed preliminary design details for a Phase 2 trial of ABS-201 in endometriosis, expected to start in mid-2027.
• Wed 9th Sep '26 · Earnings: Absci's Q2 2026 net loss was $33.2M on $0.3M of revenue, with cash up to $201.1M after the June offering and strategic Eli Lilly investment.
• Tue 11th Aug '26 · Earnings/Financing: Absci posted positive interim Phase 1 data for ABS-201 and closed a $100M offering including a $40M Eli Lilly investment, pushing its cash runway into the second half of 2028.

Bottom Line

This is a clinical-stage biotech whose entire story is its drug pipeline, not its income statement; revenue is negligible and losses are the expected cost of running clinical trials. The June 2026 raise, including a strategic investment from Eli Lilly, extended the funded runway into the second half of 2028, easing near-term cash concerns. Share count grew 24% in a year, a real dilution cost worth tracking. Upcoming Phase 1 and Phase 2 data for ABS-201 are the concrete catalysts that will likely determine where this story goes next.